Supplemental Tables and Figure

Supplemental Table 1. Basal and post-ACTH 17OHP and cortisol concentrations, CYP21A2 genotypes, and genotype group classification in 21OHD-NCAH children. Distribution of post-ACTH cortisol responses according to genotype group in 21OHD-NCAH group. Supplemental Table 2. Diagnostic performance of basal 17OHP concentrations for identifying 21OHD-NCAH among children with PP, according to cutoff values derived from ROC curve analysis. Supplemental Table 3. Clinical, demographic, and hormonal profiles between molecular control and biochemical control subgroups. Supplemental Table 4. Nutritional status and height classification based on BMI- and height-for-age z-scores according to WHO criteria in patients of molecular and biochemical control subgroups. Supplemental Figure 1. Diagnostic utility of basal and post ACTH 17-hydroxypregnenolone (17OHP) levels to identify subsequent clinical progression in patients with premature pubarche in the following 12 months. A basal cut-off of 118 ng/dL (3.6nmol/L) showed 100% sensitivity and 84% specificity, while 410 ng/dL (12.4nmol/L) maintained 100% specificity and 75% sensitivity. The optimal diagnostic balance was achieved at a cutoff of 170 ng/dL (5.1nmol/L; sensitivity 97%, specificity 91%). A post-ACTH 17OHP of 1,104 ng/dL (33.4nmol/L) provided 100% sensitivity and 100% specificity.